Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | Director | May 28, 2020 | June 01, 2020 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | May 24, 2024 | May 29, 2024 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 15, 2026 | May 16, 2026 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | June 17, 2026 | June 18, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERCEPT PHARMACEUTICALS, INC.
Report date May 28, 2020 · Filed June 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,060 |
Reported balance
After 2020-05-28 transaction · row 1
1 source rowRow 1 · 2020-05-28 · Grant · Acquired 1,595 · Balance 8,060 F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 · Expires 2030-05-28 | Direct | 2,966 |
Reported balance
After 2020-05-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-28 · Grant · Acquired 2,966 · Balance 2,966 F2: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders.
F2: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders.
Nuvation Bio Inc.
Report date May 24, 2024 · Filed May 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 659,947 |
Ending reported balance
After 2024-05-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-24 · Exercise / conversion · Acquired 293,203 · Balance 293,203 Row 2 · 2024-05-24 · Exercise / conversion · Acquired 366,744 · Balance 659,947 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-07-21 | Direct | 19,547 |
Reported balance
After 2024-05-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-24 · Exercise / conversion · Disposed 293,203 · Balance 19,547 F1: Option vests in 48 equal monthly installments from July 22, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2033-05-14 | Direct | 0 |
Reported balance
After 2024-05-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-24 · Exercise / conversion · Disposed 366,744 · Balance 0 F2: Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in 48 equal monthly installments from July 22, 2020.
F2: Option is fully vested and exercisable.
PROTHENA CORP PUBLIC LTD CO
Report date May 15, 2026 · Filed May 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.76 · Expires 2036-05-15 | Direct | 27,000 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
Structure Therapeutics Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16 | Direct | 39,453 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Ultragenyx Pharmaceutical Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,441 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 40,441 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14 | Direct | 14,058 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Acquired 1,106 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2026-02-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 35,552 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.25 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 2,454 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 2,905 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 4,750 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 0 |
Reported balance
After 2023-12-14 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-12-14 · Disposition to issuer · Disposed 10,725 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Disposition to issuer · Disposed 2,044 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:00 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 39,453 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001206199-26-000002 · form4-06182026_050603.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,453 Underlying: Ordinary Shares · 39,453 shares Expires 2036-06-16 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| May 15, 2026 Filed May 16, 2026 01:29 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $9.76 | $0.00 |
DisclosureSEC source: 0000905148-26-002471 · form4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Ordinary Shares · 27,000 shares Expires 2036-05-15 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 14,058 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001193125-26-229224 · ownership.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,058 Underlying: Common Stock · 14,058 shares Expires 2036-05-14 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-229224 · ownership.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,441 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:45 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 51,804 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001415889-25-018213 · form4-06252025_050601.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,804 Underlying: Ordinary Shares · 51,804 shares Expires 2035-06-22 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:33 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 10,787 | $0.00 Strike: $34.84 | $0.00 |
DisclosureSEC source: 0000950170-25-074667 · ownership.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Common Stock · 10,787 shares Expires 2035-05-15 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:33 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074667 · ownership.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,690 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:57 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 20,183 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000905148-25-001836 · form4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,183 Underlying: Ordinary Shares · 20,183 shares Expires 2035-05-14 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:15 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0001415889-24-018324 · form4-06272024_040601.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Ordinary Shares · 37,500 shares Expires 2034-06-24 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 25, 2024. F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 18:25 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 9,900 | $0.00 Strike: $37.42 | $0.00 |
DisclosureSEC source: 0000950170-24-075488 · ownership.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 9,900 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 18:25 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,345 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-075488 · ownership.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,950 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:38 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 366,744 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-24-014769 · form4-05292024_080529.xml · derivative · entry 4 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 366,744 shares Expires 2033-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:38 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 293,203 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-014769 · form4-05292024_080529.xml · derivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,547 Underlying: Class A Common Stock · 293,203 shares Expires 2030-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option vests in 48 equal monthly installments from July 22, 2020. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:38 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 366,744 | $1.64 | $601,460.16 |
DisclosureSEC source: 0001415889-24-014769 · form4-05292024_080529.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 659,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:38 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 293,203 | $1.74 | $510,173.22 |
DisclosureSEC source: 0001415889-24-014769 · form4-05292024_080529.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:44 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0000905148-24-001542 · form4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2034-05-15 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2025 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 132,000 | $0.00 Strike: $27.05 | $0.00 |
DisclosureSEC source: 0000905148-24-000791 · form4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,000 Underlying: Ordinary Shares · 132,000 shares Expires 2034-02-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 20% of the total number of shares subject to the option on the first anniversary of the grant date, 20% on the second anniversary of the grant date, 20% on the third anniversary of the grant date, 20% on the fourth anniversary of the grant date, and the remaining 20% on the fifth anniversary of the grant date, assuming continuous service as a director until each such vesting date. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerRestricted Stock Units · Derivative | 2,044 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-070874 · ownership.xml · derivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,044 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerCommon Stock | 10,725 | $229.00 | $2,456,025.00 |
DisclosureSEC source: 0000950170-23-070874 · ownership.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F1 · shares: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F1 · price: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 18:31 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerCommon Stock | 4,750 | $229.00 | $1,087,750.00 |
DisclosureSEC source: 0000950170-23-070874 · ownership.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F1 · shares: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F1 · price: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 18:22 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,812 | $0.00 Strike: $135.63 | $0.00 |
DisclosureSEC source: 0001203311-23-000087 · edgardoc.xml · derivative · entry 5 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,812 shares Expires 2032-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options vested in full on 5/13/23. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 18:22 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,610 | $209.08 | $336,618.80 |
DisclosureSEC source: 0001203311-23-000087 · edgardoc.xml · nonDerivative · entry 4 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 10,725 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $208.92 to $209.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 18:22 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,812 | $209.01 | $378,726.12 |
DisclosureSEC source: 0001203311-23-000087 · edgardoc.xml · nonDerivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,794 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $208.92 to $209.21. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 18:22 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,503 | $209.16 | $314,367.48 |
DisclosureSEC source: 0001203311-23-000087 · edgardoc.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,606 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F3 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $209.06 to $209.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 18:22 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 1,812 | $135.63 | $245,761.56 |
DisclosureSEC source: 0001203311-23-000087 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 21:37 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | OtherStock option (right to buy) · Derivative | 205,500 | $7.97 Strike: $2.60 | $1,637,835.00 |
DisclosureSEC source: 0001209191-23-044645 · doc4.xml · derivative · entry 3 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 205,500 Underlying: Ordinary Shares · 205,500 shares Expires 2032-01-19 F1 · kind: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares. F1 · price: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares. F2 · derivative.exercise_date: 1/3rd of the shares vested one year after January 5, 2022 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 24 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. F4 · ownership.nature: The option is held by the Michael D. Welch 2020 Irrevocable GST Trust, dated July 1, 2020. The Reporting Person is trustee of such trust and his son and such son's descendants are the sole beneficiaries of such trust. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 21:37 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | OtherStock option (right to buy) · Derivative | 205,500 | $7.97 Strike: $2.60 | $1,637,835.00 |
DisclosureSEC source: 0001209191-23-044645 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 205,500 Underlying: Ordinary Shares · 205,500 shares Expires 2032-01-19 F1 · kind: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares. F1 · price: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares. F2 · derivative.exercise_date: 1/3rd of the shares vested one year after January 5, 2022 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 24 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. F3 · ownership.nature: The option is held by the Andrew J. Welch 2020 Irrevocable GST Trust, dated July 1, 2020. The Reporting Person is trustee of such trust and his son is the sole beneficiary of such trust. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 21:37 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | OtherStock option (right to buy) · Derivative | 411,000 | $7.97 Strike: $2.60 | $3,275,670.00 |
DisclosureSEC source: 0001209191-23-044645 · doc4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 768,122 Underlying: Ordinary Shares · 411,000 shares Expires 2032-01-19 F1 · kind: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares. F1 · price: The reported transactions involve the Reporting Person's transfer of the vested portion of his option to trusts established for the benefit of his children. The transfer was a substitution for minority interests in a family limited partnership of equivalent value previously gifted to the trusts. The price per share is 1/3 of the closing price of the Issuer's American Depositary Shares ("ADS") on the date of transfer less the exercise price per share of the option. Each ADS consist of three of the Issuer's ordinary shares. F2 · derivative.exercise_date: 1/3rd of the shares vested one year after January 5, 2022 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 24 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:28 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,110 | $0.00 Strike: $51.82 | $0.00 |
DisclosureSEC source: 0001209191-23-035686 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires 2033-06-07 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:28 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035686 · doc4.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,605 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 18:18 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 2,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-23-000057 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,297 F1 · security: These securities are restricted stock units and will be settled in common stock upon vesting. F2 · shares: These restricted stock units shall vest in full on May 31, 2024. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 15, 2023 Filed May 16, 2023 19:23 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,864 | $0.00 Strike: $135.63 | $0.00 |
DisclosureSEC source: 0001203311-23-000046 · edgardoc.xml · derivative · entry 4 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,812 Underlying: Common Stock · 1,864 shares Expires 2032-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2023 Filed May 16, 2023 19:23 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,864 | $200.02 | $372,837.28 |
DisclosureSEC source: 0001203311-23-000046 · edgardoc.xml · nonDerivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,253 F1 · kind: Sales reported in this Form 4 were effected pursuant to a written plan, entered into on September 7, 2022, that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $200.00 to $200.08. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 15, 2023 Filed May 16, 2023 19:23 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 1,864 | $135.63 | $252,814.32 |
DisclosureSEC source: 0001203311-23-000046 · edgardoc.xml · nonDerivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2023 Filed May 17, 2023 21:15 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 366,744 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-23-030284 · doc4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,744 Underlying: Class A Common Stock · 366,744 shares Expires 2033-05-14 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,462 | $0.00 Strike: $147.50 | $0.00 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · derivative · entry 19 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,462 shares Expires 2031-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Options vested in full on 5/14/22. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,171 | $0.00 Strike: $160.33 | $0.00 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · derivative · entry 18 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,171 shares Expires 2030-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Options vested in full on 5/15/21. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,888 | $0.00 Strike: $64.38 | $0.00 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · derivative · entry 17 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,888 shares Expires 2029-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Options vested in full on 5/20/20. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,835 | $200.07 | $1,167,408.45 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 14 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 12,335 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F10 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $200.04 to $200.16 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 351 | $200.07 | $70,224.57 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 13 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,253 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F10 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $200.04 to $200.16 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,462 | $200.10 | $692,746.20 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 12 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,604 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F9 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $200.05 to $200.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 3,462 | $147.50 | $510,645.00 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 11 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,171 | $200.05 | $634,358.55 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 10 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,604 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F8 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $200.04 to $200.08. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 3,171 | $160.33 | $508,406.43 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 9 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 1,888 | $200.05 | $377,694.40 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 8 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,604 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F7 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $200.04 to $200.05. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 02, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 1,888 | $64.38 | $121,549.44 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 7 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,150 | $0.00 Strike: $64.38 | $0.00 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · derivative · entry 16 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,888 Underlying: Common Stock · 5,150 shares Expires 2029-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Options vested in full on 5/20/20. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,990 | $0.00 Strike: $56.77 | $0.00 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · derivative · entry 15 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,990 shares Expires 2028-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Options vested in full on 5/18/19. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,890 | $200.06 | $978,293.40 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 6 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 18,170 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F6 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $200.02 to $200.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 01, 2023 Filed May 3, 2023 21:16 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 295 | $200.06 | $59,017.70 |
DisclosureSEC source: 0000899243-23-012178 · doc4.xml · nonDerivative · entry 5 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,604 F2 · kind: Sales reported in this Form 4 were effected pursuant to written plans, entered into on September 7, 2022, that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $200.02 to $200.41. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.